Yüklüyor......
A phase I study to assess the mass balance, excretion, and pharmacokinetics of [(14)C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors
This two-part, phase I study evaluated the mass balance, excretion, pharmacokinetics (PK), and safety of ixazomib in patients with advanced solid tumors. In Part A of the study, patients received a single 4.1 mg oral solution dose of [(14)C]-ixazomib containing ~500 nCi total radioactivity (TRA), fo...
Kaydedildi:
| Yayımlandı: | Invest New Drugs |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer US
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5948259/ https://ncbi.nlm.nih.gov/pubmed/28932928 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-017-0509-1 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|